Lung Cancer Therapeutic Market

According to Stratistics MRC, the Global Lung Cancer Therapeutics Market is accounted for $37.5 billion in 2024 and is expected to reach $81.0 billion by 2030 growing at a CAGR of 13.7% during the forecast period. Lung cancer therapeutics encompasses various treatments and interventions aimed at managing or curing lung cancer, a malignancy originating in lungs' tissues. These treatments include surgery, radiation therapy, and chemotherapy. Targeted therapies focus on specific genetic mutations or abnormalities in cancer cells, using drugs like tyrosine kinase inhibitors and monoclonal antibodies. Immunotherapy uses the body's immune system to recognize and attack cancer cells, often through checkpoint inhibitors. Combination therapies, integrating various treatment modalities, have shown efficacy in advanced stages of the disease. Personalized medicine supports these treatments by tailoring treatment plans based on the patient's genetic profile.

According to the 2022 report by the American Lung Association, while the disease remains the leading cause of cancer deaths among women and men, the survival rate over the past five years has increased from 21% nationally to 25% yet remains significantly lower among communities of colour at 20%. 

Market Dynamics: 

Driver: 

Increasing incidence of lung cancer

The rise in lung cancer cases has fueled a surge in demand for various treatment options, including surgeries, chemotherapy, radiation therapy, targeted therapy, and immunotherapy. Moreover the demand for early detection and screening solutions, such as diagnostic tools and imaging technologies, is also growing, as these tools play a crucial role in identifying lung cancer early and determining the most effective treatment course. This demand has led to market growth and increased revenue for pharmaceutical companies and healthcare providers.

Restraint:

Side effects and efficacy concerns

Lung cancer treatments often have severe side effects like nausea, fatigue, immune suppression, and organ toxicity, which can reduce patient adherence and lead to suboptimal outcomes. If these treatments don't yield expected results or have limited disease progression, patients and healthcare providers may hesitate to continue, resulting in higher treatment discontinuation rates and the need for alternative, potentially more expensive, treatments hampering the market growth.

Opportunity:

Advancements in medical research

Advances in genomics and molecular biology have led to the development of targeted therapies targeting cancer cells with specific genetic mutations, improving efficacy and reducing side effects compared to traditional chemotherapy. Immunotherapy, such as immune checkpoint inhibitors, has significantly changed the treatment landscape for NSCLC, enhancing the body's immune response and potentially extending survival. In addition precision medicine has enabled personalized treatment plans based on a patient's specific cancer type and genetic makeup encourages the growth of the market.

Threat:

High treatment costs

High lung cancer treatment costs can cause financial burdens for patients, especially those without insurance, leading to delayed or missed treatment, poorer health outcomes, and reduced survival rates. This exacerbates health inequities, as low-income or underinsured populations are less likely to receive necessary care. Consequently, the economic burden of lung cancer therapy significantly impacts patient well-being and healthcare system efficiency.

Covid-19 Impact

The COVID-19 pandemic had a notable impact on the Lung Cancer Therapeutics Market, leading to disruptions in diagnosis and treatment due to healthcare system strains and patient hesitancy. Elective procedures were delayed, reducing early detection and treatment initiation rates. Clinical trials were postponed or faced recruitment challenges, slowing drug development. However, the pandemic accelerated the adoption of telemedicine and digital health solutions, which partially mitigated treatment interruptions.

The immunotherapy segment is expected to be the largest during the forecast period

The immunotherapy segment is projected to account for the largest market share during the projection period owing to particularly immune checkpoint inhibitors like pembrolizumab and nivolumab, is a key component in treating non-small cell lung cancer (NSCLC), improving survival rates and becoming the standard treatment for advanced stages. Combining immunotherapy with chemotherapy, targeted therapy, or other agents has proven more effective than monotherapy for certain patient groups, improving patient outcomes.

The hospital pharmacies segment is expected to have the highest CAGR during the forecast period

During the projection period, the hospital pharmacies segment is expected to grow at the highest CAGR because hospital pharmacies often participate in clinical trials, providing early access to new therapies and integrating the latest treatment options into clinical practice. Additionally the data collected from these operations can help understand treatment efficacy and patient outcomes, influencing future drug development and market demand.

Region with largest share:

During the estimation period, the North America region is expected to capture the largest market share owing to North America, particularly the U.S., is leading in drug development and approval of innovative lung cancer treatments, with a high concentration of pharmaceutical companies and research institutions. The presence of major regulatory bodies like the FDA and Health Canada facilitates quick approval and introduction of new drugs, making North America a hub for cutting-edge cancer therapeutics. 

Region with highest CAGR:

The Asia Pacific region is projected to achieve the highest CAGR during the forecast period because Asia Pacific region is increasingly incorporating advanced therapies like targeted therapies and immunotherapy into standard treatment protocols, particularly in wealthier countries. However, there is variability in lung cancer therapeutic availability across the region, with developed countries like Japan and South Korea having more access to innovative treatments than lower-income nations like India and Indonesia, which can affect survival rates and treatment outcomes.

Key players in the market

Some of the key players in Lung Cancer Therapeutics market include Abbvie , Amgen Inc., AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb Company, Celgene Corporation, Eli Lilly and Company, Genentech, Hoffmann-La Roche, Johnson & Johnson, Merck & Co., Millennium Pharmaceuticals, Inc., Novartis AG, Pfizer Inc., Sanofi and Teva Pharmaceutical Industries Ltd. 

Key Developments:

In November 2024, Novartis announced that the European Commission (EC) has approved Kisqali® (ribociclib) in combination with an aromatase inhibitor (AI) for the adjuvant treatment of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer (EBC) at high risk of recurrence.

In June 2024, AbbVie announced the acquisition of Celsius Therapeutics, Inc. (""Celsius""), a privately held biotechnology company pioneering new therapies for patients with inflammatory disease. Celsius' lead investigational asset is CEL383, a potential first-in-class anti-TREM1 antibody that has completed a Phase 1 clinical study for the treatment of IBD.

Types Covered:
• Non-Small Cell Lung Cancer
• Small Cell Lung Cancer
• Other Types

Therapy Types Covered:
• Immunotherapy
• Targeted Therapy
• Chemotherapy
• Radiotherapy
• Other Therapy Types

Distribution Channels Covered:
• Retail Pharmacies
• Hospital Pharmacies
• Online Pharmacies
• Specialty Cancer Treatment Centers
• Other Distribution Channels

Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o UK
o Italy
o France
o Spain
o Rest of Europe
• Asia Pacific
o Japan        
o China        
o India        
o Australia  
o New Zealand
o South Korea
o Rest of Asia Pacific    
• South America
o Argentina
o Brazil
o Chile
o Rest of South America
• Middle East & Africa 
o Saudi Arabia
o UAE
o Qatar
o South Africa
o Rest of Middle East & Africa

What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

Free Customization Offerings: 
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
o Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances